File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy

TitleUpdate on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy
Authors
KeywordsAntibiotic resistance
Clarithromycin
H. pylori eradication
Helicobacter pylori
Issue Date2006
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/DIG
Citation
Digestion, 2006, v. 73 n. 2-3, p. 101-106 How to Cite?
AbstractAim: To determine the antibiotic susceptibility of Helicobacter pylori and evaluate the efficacy of a clarithromycin-based triple therapy in relation to antibiotic resistance. Methods: Consecutive patients referred for upper endoscopy due to dyspeptic symptoms were recruited. Gastric biopsies were obtained for the CLO test, histology and culture. Antibiotic susceptibility was assessed by the E-test. Patients with H. pylori infection received rabeprazole20 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg, all twice daily for 7 days. Results: Of 234 patients recruited, 124 were H. pylori-positive and culture was successful in 102 patients. The updated prevalences of resistance to clarithromycin, amoxicillin and metronidazole were 7.8, 0 and 39.2%, respectively. A total of 86 patients received 1-week triple therapy with rabeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg, all twice daily, and 81 patients attended the follow-up test. Eradication rates by per-protocol and intention-to-treat analysis were 92.6 and 87.2%, respectively. The eradication rate by per protocol was significantly higher in patients with clarithromycin-susceptible strains than in those with clarithromycin-resistant strains (98.6 vs. 28.6%, p < 0.001). Conclusion: Clarithromycin resistance reduces the clinical efficacy of clarithromycin-based triple therapy. However, due to the low prevalence of clarithromycin resistance, clarithromycin-based therapy is still the first choice for clinical use. Copyright © 2006 S. Karger AG.
Persistent Identifierhttp://hdl.handle.net/10722/78558
ISSN
2015 Impact Factor: 1.884
2015 SCImago Journal Rankings: 0.953
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorGu, Qen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorWang, JDen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorWong, KWen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2010-09-06T07:44:12Z-
dc.date.available2010-09-06T07:44:12Z-
dc.date.issued2006en_HK
dc.identifier.citationDigestion, 2006, v. 73 n. 2-3, p. 101-106en_HK
dc.identifier.issn0012-2823en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78558-
dc.description.abstractAim: To determine the antibiotic susceptibility of Helicobacter pylori and evaluate the efficacy of a clarithromycin-based triple therapy in relation to antibiotic resistance. Methods: Consecutive patients referred for upper endoscopy due to dyspeptic symptoms were recruited. Gastric biopsies were obtained for the CLO test, histology and culture. Antibiotic susceptibility was assessed by the E-test. Patients with H. pylori infection received rabeprazole20 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg, all twice daily for 7 days. Results: Of 234 patients recruited, 124 were H. pylori-positive and culture was successful in 102 patients. The updated prevalences of resistance to clarithromycin, amoxicillin and metronidazole were 7.8, 0 and 39.2%, respectively. A total of 86 patients received 1-week triple therapy with rabeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg, all twice daily, and 81 patients attended the follow-up test. Eradication rates by per-protocol and intention-to-treat analysis were 92.6 and 87.2%, respectively. The eradication rate by per protocol was significantly higher in patients with clarithromycin-susceptible strains than in those with clarithromycin-resistant strains (98.6 vs. 28.6%, p < 0.001). Conclusion: Clarithromycin resistance reduces the clinical efficacy of clarithromycin-based triple therapy. However, due to the low prevalence of clarithromycin resistance, clarithromycin-based therapy is still the first choice for clinical use. Copyright © 2006 S. Karger AG.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/DIGen_HK
dc.relation.ispartofDigestionen_HK
dc.rightsDigestion. Copyright © S Karger AG.en_HK
dc.subjectAntibiotic resistanceen_HK
dc.subjectClarithromycinen_HK
dc.subjectH. pylori eradicationen_HK
dc.subjectHelicobacter pylorien_HK
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic useen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAmoxicillin - therapeutic useen_HK
dc.subject.meshAnti-Bacterial Agents - therapeutic useen_HK
dc.subject.meshAnti-Ulcer Agents - therapeutic useen_HK
dc.subject.meshBiopsyen_HK
dc.subject.meshBreath Testsen_HK
dc.subject.meshChi-Square Distributionen_HK
dc.subject.meshClarithromycin - therapeutic useen_HK
dc.subject.meshDrug Resistance, Bacterialen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshEndoscopy, Gastrointestinalen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHelicobacter Infections - drug therapyen_HK
dc.subject.meshHelicobacter pylori - isolation & purificationen_HK
dc.subject.meshHong Kongen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMicrobial Sensitivity Testsen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshStatistics, Nonparametricen_HK
dc.titleUpdate on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0012-2823&volume=72&issue=2-3&spage=101&epage=106&date=2006&atitle=Update+on+clarithromycin+resistance+in+Helicobacter+pylori+in+Hong+Kong+and+its+effect+on+clarithromycin-based+triple+therapy.en_HK
dc.identifier.emailWang, JD: jidewang@gmail.comen_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityWang, JD=rp00491en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000094040en_HK
dc.identifier.pmid16788304-
dc.identifier.scopuseid_2-s2.0-33746597894en_HK
dc.identifier.hkuros117742en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33746597894&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume73en_HK
dc.identifier.issue2-3en_HK
dc.identifier.spage101en_HK
dc.identifier.epage106en_HK
dc.identifier.isiWOS:000239427800005-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridGu, Q=24469982400en_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridWang, JD=35309087500en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridChan, CK=7404813824en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridWong, KW=35118458300en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats